🔗 Share this article

While the US continues making unprecedented revisions to its immunization schedules, one figure appears somewhat surprisingly: Dr. Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by questioning COVID-19 shots in the global health crisis and has focused upon alleged deaths after Covid immunization in her recent time at the FDA.

Proposed Changes to Pediatric Vaccine Schedule

Public health authorities were set to announce sweeping changes to the childhood immunization program earlier this month, bringing the US with Denmark’s immunization schedule, according to reports – a substantial departure that would put the US out of step with many the international standard with insufficient data for benefit. The planned update has been delayed until the new year.

In place of the top vaccines chief, Dr. Høeg is listed to present at the event. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth person to run the center this calendar year.

Consolidating Power at the FDA

Høeg's temporary position might represent a closer partnership between the pharmaceutical and biologics branches as Høeg and Dr. Prasad solidify control at the FDA – and it signals a renewed priority upon reevaluating previously authorized vaccines at the FDA.

Høeg has frequently advocated for ending specific childhood shot schedules in the US so as to align more similar to the Danish model, a country with comprehensive healthcare and a population approximately the population of Wisconsin’s.

In her initial public appearances, she has persisted in emphasizing on vaccination policy – typically the responsibility of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Doubts Over Expertise

The appointee has no apparent background in drug development, oversight or administrative roles, which has been standard for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“She appears not to have any of the qualifications” for running the drug-regulation department, said Jonathan Howard. “She has not conducted a scientific study. She lacks experience in running a sizeable institution. She has no expertise in pharmaceutical oversight.”

Past commissioners of CBER would “be deeply familiar with regulatory frameworks and the science of medication creation”, said Janet Woodcock. “Frankly, she lacks the type of experience that previous people who led CBER have had.”

CDER has an vast range of responsibilities at the agency, the former commissioner pointed out.

“Many people just zeroes in on the new drug program, but the generic drug division authorizes numerous generic drugs. There is also a biosimilars division, non-prescription drug unit and so forth, and every single one have to be looked after,” she explained. “The responsibility you neglect, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial management component to the role, which manages more than 5,000 employees. “It’s a massive administrative position, if you execute it properly,” she added.

Agency Reaction and Controversial Programs

In response to questions about Høeg’s credentials and whether this selection indicates greater collaboration among regulatory chiefs on vaccines, a press secretary stated that the “concerns rely on incorrect presumptions”.

“This background aligns with the duties of her position,” the spokesperson stated, citing the time Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As acting director, Høeg inherits the agency head's recently launched priority voucher program, a controversial expedited drug-approval program that allegedly worried her preceding directors. “By what process are these therapies being chosen for this voucher program? Who is making the choices?” Dr. Howard questioned. “There is a lot of lack of transparency occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the FDA seems to be moving towards more relaxed rules of all drugs, except for immunizations.”

Established Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a more documented, if concerning, track record, some experts observe. She authored a research paper using non-validated volunteer-provided data to assess the frequency of heart inflammation following Covid immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who was said to have altered data to imply Covid vaccines are pose a greater threat than they are.

Included in her “policy goals” for the current government featured altering rules for novel immunizations and ending “optional” immunizations, she remarked after the election on a podcast. At the FDA, Dr. Høeg has allegedly floated the idea of preventing adolescent males from obtaining Covid vaccines.

“She’s an all-around dogmatist who starts off with her beliefs and tailors the evidence to retrofit the evidence in a very deceptive, untruthful fashion,” Howard said.

Taking Control and a “Revenge Tour”

Dr. Høeg became part of other dissenters, {like|